Last reviewed · How we verify

NCT05951400

Progesterone Primed Protocol Versus GnRH Antagonist in With PCO Undergoing ICSI

Completed Phase 2, PHASE3 Last updated 15 April 2026
What this trial tests

Phase 2, PHASE3 trial testing Dydrogesterone Tablets in IVF in 200 participants. Completed in 5 April 2026.

Timeline
1 January 2024
Primary endpoint
30 March 2026
5 April 2026

Quick facts

Lead sponsorBeni-Suef University
PhasePhase 2, PHASE3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment200
Start date1 January 2024
Primary completion30 March 2026
Estimated completion5 April 2026
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Beni-Suef University

Who can join

Adults 20 to 40, female only, with IVF or PCO. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare the effectiveness and safety of Progesterone Primed Ovarian Stimulation protocol (PPOS) using Dydrogestrone vs GnRH Antagonist Protocol in patients with expected high ovarian response undergoing ICSI cycle

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for IVF

Currently open trials in the same condition.

Other Beni-Suef University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05951400.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing